New Strategies in Renal Cell Carcinoma: Targeting the Genetic and Metabolic Basis of Disease

The development of new forms of treatment of advanced renal cell carcinoma over the past two decades has been primarily focused on targeting the VHL/HIF pathway. The recent identification of mutations of chromatin-remodeling genes in clear-cell renal carcinoma (ccRCC), of genomic heterogeneity, and of a Warburg-like metabolic phenotype in advanced disease has had a profound effect on our understanding of the evolution of ccRCC and on potential approaches to personalized therapy. Early approaches to therapy for patients with advanced type I papillary RCC that have centered around the MET/HGF pathway will expand as more genomic information becomes available. Sporadic and familial type II papillary renal cell carcinoma are characterized by enhanced aerobic glycolysis and share an antioxidant response phenotype. In fumarate hydratase–deficient RCC, fumarate-induced succination of KEAP1 activates Nrf2 signaling. CUL3 and Nrf2 mutations as well as an Nrf2 activation phenotype are found in sporadic type II papillary RCC. Therapeutic approaches designed to target the Nrf2 pathway as well as to impair blood flow and glucose delivery in these cancers that are highly dependent on a robust tumor vasculature and on ready availability of glucose for energy production and glycolysis are in development. Clin Cancer Res; 21(1); 10–17. ©2015 AACR.

[1]  Hereditary papillary renal cell carcinoma , 2020, Definitions.

[2]  P. Lowe,et al.  Hereditary leiomyomatosis and renal cell carcinoma syndrome , 2015, The Medical journal of Australia.

[3]  G. Mills,et al.  Autophagy mediates HIF2α degradation and suppresses renal tumorigenesis , 2014, Oncogene.

[4]  S. Sarkar,et al.  SETD2-Dependent Histone H3K36 Trimethylation Is Required for Homologous Recombination Repair and Genome Stability , 2014, Cell reports.

[5]  G. Mills,et al.  Genetic and pharmacological strategies to refunctionalize the von Hippel Lindau R167Q mutant protein. , 2014, Cancer research.

[6]  J. Desterro,et al.  SETD2 is required for DNA double-strand break repair and activation of the p53-mediated checkpoint , 2014, eLife.

[7]  J. Cheville,et al.  Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low‐risk clear cell renal cell carcinoma , 2014, Cancer.

[8]  W Marston Linehan,et al.  Intratumoral heterogeneity in kidney cancer , 2014, Nature Genetics.

[9]  P. A. Futreal,et al.  Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing , 2014, Nature Genetics.

[10]  Joel S Parker,et al.  Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects , 2014, Genome research.

[11]  W. Linehan,et al.  Non-clear cell renal cancer: disease-based management and opportunities for targeted therapeutic approaches. , 2013, Seminars in oncology.

[12]  R. Motzer,et al.  Novel Approaches Targeting the Vascular Endothelial Growth Factor Axis in Renal Cell Carcinoma , 2013, Cancer journal.

[13]  H. Aburatani,et al.  Integrated molecular analysis of clear-cell renal cell carcinoma , 2013, Nature Genetics.

[14]  G. Gyapay,et al.  Germline BAP1 mutations predispose to renal cell carcinomas. , 2013, American journal of human genetics.

[15]  N. Grishin,et al.  A Novel Germline Mutation in BAP1 Predisposes to Familial Clear-Cell Renal Cell Carcinoma , 2013, Molecular Cancer Research.

[16]  W Marston Linehan,et al.  Molecular Pathways: Fumarate Hydratase-Deficient Kidney Cancer—Targeting the Warburg Effect in Cancer , 2013, Clinical Cancer Research.

[17]  C. Sander,et al.  Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators BAP1 and SETD2: A Report by MSKCC and the KIRC TCGA Research Network , 2013, Clinical Cancer Research.

[18]  Wei Yang,et al.  The Histone Mark H3K36me3 Regulates Human DNA Mismatch Repair through Its Interaction with MutSα , 2013, Cell.

[19]  Karl J. Dykema,et al.  CUL3 and NRF2 mutations confer an NRF2 activation phenotype in a sporadic form of papillary renal cell carcinoma. , 2013, Cancer research.

[20]  G. Stephanopoulos,et al.  Cofactor Balance by Nicotinamide Nucleotide Transhydrogenase (NNT) Coordinates Reductive Carboxylation and Glucose Catabolism in the Tricarboxylic Acid (TCA) Cycle*♦ , 2013, The Journal of Biological Chemistry.

[21]  G. Stephanopoulos,et al.  In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation. , 2013, Cell metabolism.

[22]  W. Kaelin,et al.  The VHL/HIF axis in clear cell renal carcinoma. , 2013, Seminars in cancer biology.

[23]  R. Srinivasan,et al.  Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  W Marston Linehan,et al.  Genetic basis of kidney cancer: Role of genomics for the development of disease-based therapeutics , 2012, Genome research.

[25]  James B. Mitchell,et al.  Targeting HIF2α Translation with Tempol in VHL-Deficient Clear Cell Renal Cell Carcinoma , 2012, Oncotarget.

[26]  T. Grkovic,et al.  Inhibition of hypoxia inducible factor-2 transcription: isolation of active modulators from marine sponges. , 2012, Journal of natural products.

[27]  R. Motzer,et al.  Ten years of progress in renal cell carcinoma. , 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

[28]  N. Grishin,et al.  BAP1 loss defines a new class of renal cell carcinoma , 2012, Nature Genetics.

[29]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[30]  Huanming Yang,et al.  Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma , 2011, Nature Genetics.

[31]  Christian M. Metallo,et al.  Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia , 2011, Nature.

[32]  E. Jonasch,et al.  Chromosome 14q loss defines a molecular subtype of clear-cell renal cell carcinoma associated with poor prognosis , 2011, Modern Pathology.

[33]  Ximing J. Yang,et al.  An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. , 2011, Cancer cell.

[34]  P. Carmeliet,et al.  Renal Cyst Formation in Fh1-Deficient Mice Is Independent of the Hif/Phd Pathway: Roles for Fumarate in KEAP1 Succination and Nrf2 Signaling , 2011, Cancer cell.

[35]  W. Marston Linehan,et al.  Reductive carboxylation supports growth in tumor cells with defective mitochondria , 2011, Nature.

[36]  R. Sougrat,et al.  The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels. , 2011, Cancer cell.

[37]  Rameen Beroukhim,et al.  Genetic and functional studies implicate HIF1α as a 14q kidney cancer suppressor gene. , 2011, Cancer discovery.

[38]  Xiuping Liu,et al.  The hypoxia-associated factor switches cells from HIF-1α- to HIF-2α-dependent signaling promoting stem cell characteristics, aggressive tumor growth and invasion. , 2011, Cancer research.

[39]  K. Gustafson,et al.  Identification and evaluation of soft coral diterpenes as inhibitors of HIF-2α induced gene expression. , 2011, Bioorganic & medicinal chemistry letters.

[40]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[41]  B. Viollet,et al.  AMPK as a therapeutic target in renal cell carcinoma , 2010, Cancer biology & therapy.

[42]  P. A. Futreal,et al.  Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma , 2010, Nature.

[43]  W. Linehan,et al.  The genetic basis of kidney cancer: a metabolic disease , 2010, Nature Reviews Urology.

[44]  Benjamin L Ebert,et al.  The connectivity map links iron regulatory protein-1-mediated inhibition of hypoxia-inducible factor-2a translation to the anti-inflammatory 15-deoxy-delta12,14-prostaglandin J2. , 2010, Cancer research.

[45]  Gurpreet W. Tang,et al.  Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes , 2009, Nature.

[46]  W. Linehan,et al.  LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer , 2009, Molecular Cancer Therapeutics.

[47]  T. Golub,et al.  Small-molecule inhibitors of HIF-2a translation link its 5'UTR iron-responsive element to oxygen sensing. , 2008, Molecular cell.

[48]  G. Powis,et al.  Hypoxia-Associated Factor, a Novel E3-Ubiquitin Ligase, Binds and Ubiquitinates Hypoxia-Inducible Factor 1α, Leading to Its Oxygen-Independent Degradation , 2008, Molecular and Cellular Biology.

[49]  F. Waldman,et al.  Improved Identification of von Hippel-Lindau Gene Alterations in Clear Cell Renal Tumors , 2008, Clinical Cancer Research.

[50]  J. Engelman,et al.  A sweet new role for EGFR in cancer. , 2008, Cancer cell.

[51]  P. Choyke,et al.  Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. , 2007, The Journal of urology.

[52]  W. Linehan,et al.  Development of a Cell-Based Reporter Assay for Screening of Inhibitors of Hypoxia-Inducible Factor 2-Induced Gene Expression , 2006, Journal of biomolecular screening.

[53]  Yuen-Li Chung,et al.  HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. , 2005, Cancer cell.

[54]  O. Iliopoulos,et al.  Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors. , 2004, Molecular cancer research : MCR.

[55]  W. Kaelin,et al.  Inhibition of HIF2α Is Sufficient to Suppress pVHL-Defective Tumor Growth , 2003, PLoS biology.

[56]  A. Paetau,et al.  Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer , 2002, Nature Genetics.

[57]  Mirna Lechpammer,et al.  Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. , 2002, Cancer cell.

[58]  Richard D Klausner,et al.  The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. , 2002, Cancer cell.

[59]  Michael I. Wilson,et al.  Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation , 2001, Science.

[60]  M. Ivan,et al.  HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O2 Sensing , 2001, Science.

[61]  L. Aaltonen,et al.  Inherited susceptibility to uterine leiomyomas and renal cell cancer , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[62]  P. Choyke,et al.  Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. , 1999, The American journal of pathology.

[63]  W. Marston Linehan,et al.  Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas , 1998, Nature Genetics.

[64]  P. Choyke,et al.  Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. , 1998, Cancer research.

[65]  S. Scherer,et al.  Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas , 1997, Nature Genetics.

[66]  D. Duan,et al.  Inhibition of transcription elongation by the VHL tumor suppressor protein , 1995, Science.

[67]  J. Gnarra,et al.  Identification of the von Hippel-Lindau disease tumor suppressor gene. , 1993, Science.

[68]  O. Warburg [Origin of cancer cells]. , 1956, Oncologia.

[69]  J. Graham,et al.  METABOLISM OF CANCER CELLS , 1955 .

[70]  Paolo Vineis,et al.  Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3 , 2011, Nature Genetics.

[71]  W. Linehan,et al.  A new hypoxia inducible factor-2 inhibitory pyrrolinone alkaloid from roots and stems of Piper sarmentosum. , 2011, Chemical & pharmaceutical bulletin.

[72]  W. Linehan,et al.  UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer. , 2010, Cancer genetics and cytogenetics.